<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92499">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02020954</url>
  </required_header>
  <id_info>
    <org_study_id>Becker-Heart-Study</org_study_id>
    <nct_id>NCT02020954</nct_id>
  </id_info>
  <brief_title>Prospective Becker-Heart-Study</brief_title>
  <acronym>Becker-HS</acronym>
  <official_title>Prospective Cohort Study of Patients With Mutations in the Dystrophin Gene (X Linked Dilated Cardiomyopathy and Becker Muscular Dystrophy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karim WAHBI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Myologie, France</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether electrocardiogram, echocardiography,
      cardiac MRI, sera biomarkers can improve early detection of myocardial involvement and
      clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cohort of 100 patients with mutations in the dystrophin gene associated with Becker
      muscular dystrophy and/or dilated cardiomyopathy will be included (patients with Duchenne
      muscular dystrophy are excluded).

      Patients with undergo at baseline the following workups: electrocardiogram,
      echocardiography, cardiac MRI, sera biomarkers measurement.

      At 3 years and 5 years, patients will be investigated according to the same protocol and
      occurrence of cardiac adverse events in the meanwhile will be recorded.

      Statistical analysis will assess correlations between cardiac phenotype and DMD mutations
      and prognostic value of cardiac investigations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint: hospitalisation for heart failure, death due to heart failure</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Lef Ventricular Dysfunction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Dystrophinopathy</arm_group_label>
    <description>Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECG, echocardiography, cardiac MRI, sera biomarkers</intervention_name>
    <arm_group_label>Dystrophinopathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated
        cardiomyopathy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mutation in the DMD gene

          -  Becker muscular dystrophy and/or dilated cardiomyopathy

          -  age&gt;18 years

          -  affiliation to the French medical insurance

        Exclusion Criteria:

          -  Duchenne muscular dystrophy

          -  Any other chronic disease that may be associated with heart disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Wahbi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Myologie, Cochin Hospital, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim Wahbi, MD, PhD</last_name>
    <email>karim.wahbi@cch.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nawal Berber, PhD</last_name>
      <email>n.benammar@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Karim Wahbi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Myologie, France</investigator_affiliation>
    <investigator_full_name>Karim WAHBI</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
